Twenty-five health groups signed on to a letter to the Trump administration, urging that FDA be exempted from the requirement to submit proposed rules for review by Congress and the administration.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
